Compare Ecopetrol SA (EC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Neurocrine Biosciences Inc — how do they compare? Ecopetrol SA trades at $16.93 (market cap $33.11B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Ecopetrol SA is far larger — about 2.3× Neurocrine Biosciences Inc's market cap, and Ecopetrol SA pays a 3.83% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EC | NBIX | |
|---|---|---|
Market Cap | $33.11B | $14.36B |
Volume | 993,598 | 1,237,180 |
Sector | Energy | Health |
52-Week High | $18.26 | $185.50 |
52-Week Low | $8.61 | $123.10 |
Typical Hold Time | 84 Days | 23 Days |
Enterprise Value | $61.36B | $14.37B |
Dividend Yield | 3.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.63, down 1.95% with bearish technical signals. The stock shows attractive valuation metrics with P/E of 7.99 and EV/EBITDA of 4.04, but faces declining revenue from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while the company maintains solid profitability with 11.37% net margin and 17.67% ROE.
EC presents a mixed outlook with undervalued fundamentals against operational challenges. Investment opportunity lies in discounted valuation and potential stabilization under new leadership, but risks include persistent revenue decline, political interference, and negative cash flow trends. Analyst consensus remains cautious with 54.55% hold rating and $16.85 price target, slightly above current levels.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
